Other combinations are in phase I/II investigation [125] (NCT02555189, NCT02905318), and given the promising efficacy in breast cancer bone metastasis, it is of interest to determine whether CDK4/6i could be similarly effective in prostate cancer bone metastasis. This evidence concerns the gene CDK4 and prostate cancer.